Becton Dickinson Announces CFO Transition Plan

Becton Dickinson ( (BDX) ) has issued an announcement.

On October 15, 2025, BD announced a CFO transition plan as Chris DelOrefice will depart on December 5, 2025, with Vitor Roque stepping in as interim CFO. The company also reported preliminary unaudited revenue results for the fourth quarter and full year fiscal 2025, showing significant growth across various segments despite challenges in the macro environment. BD continues to focus on strategic goals and investments to drive growth and margin momentum.

The most recent analyst rating on (BDX) stock is a Hold with a $203.00 price target. To see the full list of analyst forecasts on Becton Dickinson stock, see the BDX Stock Forecast page.

Spark’s Take on BDX Stock

According to Spark, TipRanks’ AI Analyst, BDX is a Neutral.

Becton Dickinson’s overall stock score is driven by strong earnings call performance and strategic initiatives, despite challenges in valuation and technical indicators. The company’s financial performance remains stable, but profitability and cash flow improvements are needed. The high P/E ratio and mixed technical signals suggest caution, while the earnings call provides a positive outlook with strategic growth initiatives.

To see Spark’s full report on BDX stock, click here.

More about Becton Dickinson

Becton, Dickinson and Company (BD) is a leading global medical technology firm that specializes in the development and sale of medical devices, instrument systems, and reagents. The company focuses on advancing healthcare by improving medical discovery, diagnostics, and the delivery of care.

Average Trading Volume: 2,038,995

Technical Sentiment Signal: Sell

Current Market Cap: $53.5B

For a thorough assessment of BDX stock, go to TipRanks’ Stock Analysis page.